Entry Point Capital, LLC Takeda Pharmaceutical CO LTD Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Takeda Pharmaceutical CO LTD stock. As of the latest transaction made, Entry Point Capital, LLC holds 15,804 shares of TAK stock, worth $204,187. This represents 0.13% of its overall portfolio holdings.
Number of Shares
15,804Holding current value
$204,187% of portfolio
0.13%Shares
1 transactions
Others Institutions Holding TAK
# of Institutions
336Shares Held
73.8MCall Options Held
1.96MPut Options Held
165K-
Capital Research Global Investors Los Angeles, CA13.1MShares$170 Million0.04% of portfolio
-
Morgan Stanley New York, NY5.35MShares$69.2 Million0.01% of portfolio
-
Mondrian Investment Partners LTD London, X05.09MShares$65.8 Million1.21% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA4.64MShares$59.9 Million0.05% of portfolio
-
Goldman Sachs Group Inc New York, NY4.56MShares$58.9 Million0.01% of portfolio
About TAKEDA PHARMACEUTICAL CO LTD
- Ticker TAK
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 3,109,050,112
- Market Cap $40.2B
- Description
- Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived t...